A medical oncologist at a Northeast Academic NCI Comprehensive Cancer Center discusses their utilization and understanding of MRD and ctDNA monitoring in patients with bladder, renal, and prostate cancers. Currently, they are most familiar with these technologies in bladder, and are most optimistic about post-surgical MRD as compared to ctDNA monitoring due to lack of data in the latter. They are most familiar with Natera for MRD testing, though they are open to changing vendors in the future based on who has the most promising data specific to the patient populations they treat. They have already adopted MRD as a tool to help risk-stratify patients and in cases when they are resistant to treatment suggestions, test results can help rationalize this oncologists recommendations.

Campaign Details

MRD Ad Board

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care